Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Cross-Cultural Validation of the RECAP of Atopic Eczema Questionnaire in a Swedish Population

Sigurdardottir, Gunnthorunn ; Alsterholm, Mikael ; Anderson, Chris D. ; Bradley, Maria ; Sandström Falk, Marihelen ; Johansson, Emma K. ; Lundqvist, Maria ; Sonesson, Andreas LU ; Svensson, Åke LU and Theodosiou, Grigorios LU orcid , et al. (2024) In Acta Dermato-Venereologica 104.
Abstract

A Swedish translation of the patient-reported outcome measure for assessing long-term control of atopic der-matitis, Recap of atopic eczema (RECAP), has not been validated. Cross-cultural translation and multi-centre validation of the translated RECAP questionnaire were therefore performed. Disease severity was assessed using the validated Investigator Global Assessment Scale for atopic dermatitis (vIGA-AD™). The Swedish RECAP was completed by 208 individuals aged 16 years or older with a median age of 36 years (inter-quartile range [IQR] 27–48). The participants consi-dered the questionnaire suitable for assessing eczema control. The median RECAP score (range 0–28) was 12 (IQR 5–19). The mean and median vIGA-AD™ scores (range 0–4) were... (More)

A Swedish translation of the patient-reported outcome measure for assessing long-term control of atopic der-matitis, Recap of atopic eczema (RECAP), has not been validated. Cross-cultural translation and multi-centre validation of the translated RECAP questionnaire were therefore performed. Disease severity was assessed using the validated Investigator Global Assessment Scale for atopic dermatitis (vIGA-AD™). The Swedish RECAP was completed by 208 individuals aged 16 years or older with a median age of 36 years (inter-quartile range [IQR] 27–48). The participants consi-dered the questionnaire suitable for assessing eczema control. The median RECAP score (range 0–28) was 12 (IQR 5–19). The mean and median vIGA-AD™ scores (range 0–4) were 2 (standard deviation [SD] 2) and 3 (IQR 2–4), respectively. A correlation between RECAP and the vIGA-AD™ was observed (p < 0.001). There was no significant change in scores for participants who answered the questionnaire twice within 14 days. Over time, improved or worsened eczema, as evaluated by vIGA-AD™, affected RECAP scores significantly (p < 0.001). The study suggests that RECAP can assess AD control in a Swedish clinical setting and shows acceptable reliability.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
atopic dermatitis, eczema, patient-reported outcome measure, validation study
in
Acta Dermato-Venereologica
volume
104
article number
adv38889
publisher
Medical Journals Limited
external identifiers
  • pmid:38898676
  • scopus:85196697694
ISSN
0001-5555
DOI
10.2340/actadv.v104.38889
language
English
LU publication?
yes
id
3f227744-d5e1-4bb0-b40a-e7040085809b
date added to LUP
2024-08-15 10:46:24
date last changed
2024-08-16 03:04:06
@article{3f227744-d5e1-4bb0-b40a-e7040085809b,
  abstract     = {{<p>A Swedish translation of the patient-reported outcome measure for assessing long-term control of atopic der-matitis, Recap of atopic eczema (RECAP), has not been validated. Cross-cultural translation and multi-centre validation of the translated RECAP questionnaire were therefore performed. Disease severity was assessed using the validated Investigator Global Assessment Scale for atopic dermatitis (vIGA-AD™). The Swedish RECAP was completed by 208 individuals aged 16 years or older with a median age of 36 years (inter-quartile range [IQR] 27–48). The participants consi-dered the questionnaire suitable for assessing eczema control. The median RECAP score (range 0–28) was 12 (IQR 5–19). The mean and median vIGA-AD™ scores (range 0–4) were 2 (standard deviation [SD] 2) and 3 (IQR 2–4), respectively. A correlation between RECAP and the vIGA-AD™ was observed (p &lt; 0.001). There was no significant change in scores for participants who answered the questionnaire twice within 14 days. Over time, improved or worsened eczema, as evaluated by vIGA-AD™, affected RECAP scores significantly (p &lt; 0.001). The study suggests that RECAP can assess AD control in a Swedish clinical setting and shows acceptable reliability.</p>}},
  author       = {{Sigurdardottir, Gunnthorunn and Alsterholm, Mikael and Anderson, Chris D. and Bradley, Maria and Sandström Falk, Marihelen and Johansson, Emma K. and Lundqvist, Maria and Sonesson, Andreas and Svensson, Åke and Theodosiou, Grigorios and Vrang, Sophie and Kobyletzki, Laura B.von}},
  issn         = {{0001-5555}},
  keywords     = {{atopic dermatitis; eczema; patient-reported outcome measure; validation study}},
  language     = {{eng}},
  month        = {{06}},
  publisher    = {{Medical Journals Limited}},
  series       = {{Acta Dermato-Venereologica}},
  title        = {{Cross-Cultural Validation of the RECAP of Atopic Eczema Questionnaire in a Swedish Population}},
  url          = {{http://dx.doi.org/10.2340/actadv.v104.38889}},
  doi          = {{10.2340/actadv.v104.38889}},
  volume       = {{104}},
  year         = {{2024}},
}